# Waycross Ventures

> Waycross Ventures is a VC fund in Menlo Park backing Biotechnology and Medical. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Menlo Park, United States
- Total investments: 7
- Last investment: May 2024
- Lead investor: 0%
- Last updated: Aug 2026

Waycross Ventures is a venture capital firm. It is headquartered in Menlo Park, California.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 71% |
| Medical | 3 | 43% |
| Health Care | 3 | 43% |
| Life Science | 2 | 29% |
| EdTech | 1 | 14% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 29% |
| Series C | 2 | 29% |
| Series D | 2 | 29% |
| Series A | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Karius | Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a majorthreat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing. | $100M | Series C | May 02, 2024 |  |
| Delphinus Medical Technologies | Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presenceof benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan. | $30.4M | Series D | Sep 13, 2022 |  |
| ArsenalBio | ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughputtarget identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. | $220.8M | Series B | Sep 06, 2022 |  |
| Neumora Therapeutics | Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. | $400M | Series A | Oct 07, 2021 |  |
| Newsela | Newsela is an Edtech startup that takes real and new content from trusted providers and turns it into learning materials. | $100M | Series D | Feb 25, 2021 |  |
| Delphinus Medical Technologies | Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presenceof benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan. | $39.5M | Series C | Sep 10, 2015 |  |
| Verana Health | Verana Health is a digital health data company that delivers insights from unfiltered healthcare data with integrity to connect the dots between patient care and clinical research. Verana Health is exclusively entrusted by key specialty medical societies to manage data from real-world healthcare settings across more than 20,000 healthcare providersand 70 electronic health record systems. Its healthcare data ecosystem is powered by VeraQ™, a clinician-directed and AI-enhanced population health data engine that securely powers a data integrity feedback loop of nearly a half-billion raw, point-of-care health encounters. By applying advanced analytics to proprietary, curated datasets, Qdata™, Verana Health helps life sciences partners enhance evidence generation and speed clinical research that promote physicians’ quality of care and patients’ quality of life. For more information, visit www.veranahealth.com. | $7.8M | Series B | Feb 09, 2015 |  |

7 of 7 investments shown.

## Co-investors
- [Arboretum Ventures](https://shizune.co/investors/profile/arboretum-ventures) — VC Fund, 3 deals together
- [SoftBank Vision Fund](https://shizune.co/investors/profile/softbank-vision-fund) — VC Fund, 3 deals together
- [Beringea](https://shizune.co/investors/profile/beringea) — VC Fund, 2 deals together
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 2 deals together
- Hopen Life Science Ventures — VC Fund, 2 deals together
- [Kleiner Perkins](https://shizune.co/investors/profile/kleiner-perkins-caufield-byers) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Waycross Ventures invest in?

Waycross Ventures invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Waycross Ventures last invest?

The most recent investment recorded for Waycross Ventures closed in May 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co